This ongoing international phase 3 trial is evaluating HER2-positive GC/GEJC in 692 patients treated with pembrolizumab or placebo plus trastuzumab and chemotherapy (capecitabine + oxaliplatin or fluorouracil + cisplatin). This evidence concerns the gene ERBB2 and gastric cancer.